In humans, antibodies that inhibit immune checkpoint molecules, such as programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1), have demonstrated robust antitumor efficacies with acceptable safety profiles for various cancer types1–3. This evidence concerns the gene CD274 and cancer.